Perspectives on PARP Inhibition and Ovarian Cancer
Expert Perspectives
Expert Perspectives

Perspectives on PARP Inhibition and Ovarian Cancer

Leading the Field in Exploiting DNA Repair as a Therapeutic Target

Not a member of My prIME? Join now for instant access.

Enhance your understanding of the use of PARP inhibitors in ovarian cancer with expert perspective videos, where a variety of topics will be discussed, including DNA repair and PARP inhibition, use of PARP inhibitors in various settings, practical considerations for PARP inhibitor therapy in the clinic, and future directions.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

IME

IME

Release Date

Release Date

Dec 1, 2017

Expiration Date

Dec 4, 2018

Faculty

  • Nicoletta Colombo, MDUniversity of Milan–Bicocca
    European Institute of Oncology
    Milan, Italy
  • Thomas Helleday, PhDKarolinska Institute
    Stockholm, Sweden
  • Rebecca Kristeleit, MD, PhDUCL Cancer Institute
    University College London
    London, United Kingdom
  • Bradley J. Monk, MD, FACS, FACOGArizona Oncology (US Oncology Network), University of Arizona College of Medicine-Phoenix
    Creighton University School of Medicine at St. Joseph's Hospital
    Phoenix, Arizona, United States

Introduction
Nicoletta Colombo, MD

Everything a clinician needs to know about DNA repair and PARP inhibition
Thomas Helleday, PhD

A new string to the bow in the treatment of advanced ovarian cancer
Bradley J. Monk, MD, FACS, FACOG

Clinical application of PARP inhibitors: Proactive management of adverse events
Rebecca Kristeleit, MD, PhD

This educational activity is designed for oncologists, gynecologists, and other healthcare professionals interested and/or involved in the use of PARP inhibitors for the treatment of patients with ovarian cancer.

After successful completion of this educational activity, participants should be able to:

  • Describe current and emerging biomarkers that assess genomic instability and evaluate defects in DNA repair
  • Evaluate emerging clinical data and ongoing trials involving PARP inhibition for patients with BRCA 1/2 mutant and wildtype ovarian cancer
  • Assess the adverse events associated with PARP inhibition for ovarian cancer and how best to ensure long-term adherence to PARP inhibitors

This educational activity is supported by a grant from Clovis Oncology, Inc.

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.

Provider

This enduring activity is provided by prIME Oncology.

Disclosure Information

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.